The metabolic response to the activation of the β-adrenergic receptor by salbutamol is amplified by acylated ghrelin

Journal of Endocrinological Investigation

Volumn 33, Issue 6, 2010, Pages 363-367

  St Pierre, D H ^a   Benso, A ^a   Gramaglia, E ^a   Prodam, F ^a   Lucatello, B ^a   Ramella Gigliardi, V ^a   Olivetti, I ^a   Tomelini, M ^a   Broglio, F ^a  

^a MOLINETTE HOSPITAL   (Italy)

Author keywords

Acylated ghrelin; Glucose; Insulin; Lipids; Salbutamol; adrenergic receptor

Indexed keywords

ACYLATED GHRELIN; BETA ADRENERGIC RECEPTOR; FATTY ACID; GHRELIN; GHRELIN RECEPTOR; GLUCOSE; INSULIN; ISOTONIC SOLUTION; SALBUTAMOL; UNCLASSIFIED DRUG; GLUCOSE BLOOD LEVEL; HUMAN GROWTH HORMONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG EFFECT; DRUG HALF LIFE; FATTY ACID BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HUMAN EXPERIMENT; INSULIN BLOOD LEVEL; INSULIN LIKE ACTIVITY; INSULIN RELEASE; MALE; NORMAL HUMAN; ACYLATION; BLOOD; CONTROLLED STUDY; DRUG EFFECTS; LIPOLYSIS; METABOLISM; RANDOMIZED CONTROLLED TRIAL; SECRETION (PROCESS);

ACYLATION; ADULT; ALBUTEROL; BLOOD GLUCOSE; FATTY ACIDS, NONESTERIFIED; GHRELIN; HUMAN GROWTH HORMONE; HUMANS; INSULIN; LIPOLYSIS; MALE; RECEPTORS, ADRENERGIC, BETA;

EID: 77955354438     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.1007/BF03346604     Document Type: Article

References (45)

1. Porte D Jr, Graber AL, Kuzuya T, Williams RH. The effect of epinephrine on immunoreactive insulin levels in man. J Clin Invest 1966, 45: 228-36.
2. Porte D Jr. A receptor mechanism for the inhibition of insulin release by epinephrine in man. J Clin Invest 1967, 46: 86-94.
3. Imura H, Kato Y, Ikeda M, Morimoto M, Yawata M. Effect of adrenergic-blocking or -stimulating agents on plasma growth hormone, immunoreactive insulin, and blood free fatty acid levels in man. J Clin Invest 1971, 50: 1069-79.
4. Gluckman PD. The development of beta-adrenergic mediated inhibition of growth hormone secretion in the ovine fetus. J Dev Physiol 1982, 4: 207-14.
5. Bluet-Pajot MT, Durand D, Mounier F, Schaub C, Kordon C. Interaction of beta-adrenergic agonists and antagonists with the stimulation of growth hormone release induced by Clonidine or by morphine in the rat. J Endocrinol 1982, 94: 327-31. (Pubitemid 12064254)
6. Kim J, Shigetomi S, Tanaka K, Yamada ZO, Hashimoto S, Fukuchi S. [The role of beta 2-adrenoceptor on the pathogenesis of insulin resistance in essential hypertension]. Nippon Naibunpi Gakkai Zasshi 1994, 70: 521-8.
7. Muccioli G, Pons N, Ghè C, Catapano F, Granata R, Ghigo E. Ghrelin and des-acyl ghrelin both inhibit isoproterenol-induced lipolysis in rat adipocytes via a non-type 1a growth hormone secretagogue receptor. Eur J Pharmacol 2004, 498: 27-35. (Pubitemid 39208057)
8. Park HS, Shin ES, Lee JE. Genotypes and haplotypes of beta2-adrenergic receptor and parameters of the metabolic syndrome in Korean adolescents. Metabolism 2008, 57: 1064-70.
9. Palmer JP, Halter J, Werner PL. Differential effect of isoproterenol on acute glucagon and insulin release in man. Metabolism 1979, 28: 237-40. (Pubitemid 9138465)
10. Kuusela P, Rehnmark S, Jacobsson A, Cannon B, Nedergaard J. Adrenergic stimulation of lipoprotein lipase gene expression in rat brown adipocytes differentiated in culture: mediation via beta3-and alpha1-adrenergic receptors. Biochem J 1997, 321 (Pt 3): 759-67. (Pubitemid 27084886)
11. Ghigo E, Valetto MR, Gaggero L, et al. Therapeutical doses of salbutamol inhibit the somatotropic responsiveness to growth hormone-releasing hormone in asthmatic children. J Endocrinol Invest 1993, 16: 271-5. (Pubitemid 23185920)
12. Ghigo E, Arvat E, Gianotti L, et al. Interaction of salbutamol with pyridostigmine and arginine on both basal and GHRH-stimulated GH secretion in humans. Clin Endocrinol (Oxf) 1994, 40: 799-802. (Pubitemid 24216631)
13. Arvat E, Gianotti L, Ramunni J, et al. Influence of beta-adrenergic agonists and antagonists on the GH-releasing effect of Hexarelin in man. J Endocrinol Invest 1996, 19: 25-9. (Pubitemid 26090513)
14. Hosoda H, Kangawa K. The autonomic nervous system regulates gastric ghrelin secretion in rats. Regul Pept 2008, 146: 12-8.
15. Adeghate E, Ponery AS. Ghrelin stimulates insulin secretion from the pancreas of normal and diabetic rats. J Neuroendocrinol 2002, 14: 555-60. (Pubitemid 34679218)
16. Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999, 402: 656-60. (Pubitemid 129516334)
17. Wiedmer P, Nogueiras R, Broglio F, D'Alessio D, Tschop MH. Ghrelin, obesity and diabetes. Nat Clin Pract Endocrinol Metab 2007, 3: 705-12.
18. Tschöp M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature 2000, 407: 908-13.
19. Wren AM, Small CJ, Ward HL, et al. The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology 2000, 141: 4325-8.
20. De Vriese C, Delporte C. Influence of ghrelin on food intake and energy homeostasis. Curr Opin Clin Nutr Metab Care 2007, 10: 615-9. (Pubitemid 47254724)
21. Shiiya T, Nakazato M, Mizuta M, et al. Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab 2002, 87: 240-4. (Pubitemid 34084697)
22. St-Pierre DH, Karelis AD, Coderre L, et al. Association of acylated and nonacylated ghrelin with insulin sensitivity in overweight and obese postmenopausal women. J Clin Endocrinol Metab 2007, 92: 264-9. (Pubitemid 46067542)
23. Cummings DE, Weigle DS, Frayo RS, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002, 346: 1623-30.
24. Broglio F, Gottero C, Prodam F, et al. Non-acylated ghrelin counteracts the metabolic but not the neuroendocrine response to acylated ghrelin in humans. J Clin Endocrinol Metab 2004, 89: 3062-5. (Pubitemid 38766409)
25. Choi K, Roh SG, Hong YH, et al. The role of ghrelin and growth hormone secretagogues receptor on rat adipogenesis. Endocrinology 2003, 144: 754-9. (Pubitemid 36262842)
26. Theander-Carrillo C, Wiedmer P, Cettour-Rose P, et al. Ghrelin action in the brain controls adipocyte metabolism. J Clin Invest 2006, 116: 1983-93. (Pubitemid 44033322)
27. Rigault C, Le Borgne F, Georges B, Demarquoy J. Ghrelin reduces hepatic mitochondrial fatty acid beta oxidation. J Endocrinol Invest 2007, 30: RC4-8.
28. Barazzoni R, Bosutti A, Stebel M, et al. Ghrelin regulates mitochondrial-lipid metabolism gene expression and tissue fat distribution in liver and skeletal muscle. Am J Physiol Endocrinol Metab 2005, 288: E228-35.
29. Vestergaard ET, Djurhuus CB, Gjedsted J, et al. Acute effects of ghrelin administration on glucose and lipid metabolism. J Clin Endocrinol Metab 2008, 93: 438-44. (Pubitemid 351240813)
30. Broglio F, Prodam F, Riganti F, et al. The continuous infusion of acylated ghrelin enhances growth hormone secretion and worsens glucose metabolism in humans. J Endocrinol Invest 2008, 31: 788-94.
31. Vestergaard ET, Gormsen LC, Jessen N, et al. Ghrelin infusion in humans induces acute insulin resistance and lipolysis independent of growth hormone signaling. Diabetes 2008, 57: 3205-10.
32. Date Y, Shimbara T, Koda S, et al. Peripheral ghrelin transmits orexigenic signals through the noradrenergic pathway from the hindbrain to the hypothalamus. Cell Metab 2006, 4: 323-31.
33. Massara F, Fassio V, Camanni F, Martina V, Molinatti G. Some metabolic and hormonal effects of salbutamol in man. Acta Diabetol Lat 1976, 13: 146-53.
34. Tickner TR, Cramp DG, Foo AY, et al. Metabolic response to intravenous salbutamol therapy in acute asthma. Thorax 1977, 32: 182-4.
35. Hoeks J, van Baak MA, Hesselink MK, et al. Effect of beta1- and beta2-adrenergic stimulation on energy expenditure, substrate oxidation, and UCP3 expression in humans. Am J Physiol Endocrinol Metab 2003, 285: E775-82.
36. Fusco A, Bianchi A, Mancini A, et al. Effects of ghrelin administration on endocrine and metabolic parameters in obese women with polycystic ovary syndrome. J Endocrinol Invest 2007, 30: 948-56.
37. Vestergaard ET, Hansen TK, Gormsen LC, et al. Constant intravenous ghrelin infusion in healthy young men: clinical pharmacokinetics and metabolic effects. Am J Physiol Endocrinol Metab 2007, 292: E1829-36.
38. van der Lely AJ, Tschop M, Heiman ML, Ghigo E. Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev 2004, 25: 426-57.
39. Paik KH, Choe YH, Park WH, et al. Suppression of acylated ghrelin during oral glucose tolerance test is correlated with whole-body insulin sensitivity in children with Prader-Willi syndrome. J Clin Endocrinol Metab 2006, 91: 1876-81.
40. Gauna C, Delhanty PJ, Hofland LJ, et al. Ghrelin stimulates, whereas des-octanoyl ghrelin inhibits, glucose output by primary hepatocytes. J Clin Endocrinol Metab 2005, 90: 1055-60.
41. Gauna C, Meyler FM, Janssen JA, et al. Administration of acylated ghrelin reduces insulin sensitivity, whereas the combination of acylated plus unacylated ghrelin strongly improves insulin sensitivity. J Clin Endocrinol Metab 2004, 89: 5035-42.
42. Lucidi P, Murdolo G, Di Loreto C, et al. Metabolic and endocrine effects of physiological increments in plasma ghrelin concentrations. Nutr Metab Cardiovasc Dis 2005, 15: 410-7.
43. Whyte KF, Addis GJ, Whitesmith R, Reid JL. Adrenergic control of plasma magnesium in man. Clin Sci (Lond) 1987, 72: 135-8.
44. Whyte KF, Addis GJ, Whitesmith R, Reid JL. The mechanism of salbutamol-induced hypokalaemia. Br J Clin Pharmacol 1987, 23: 65-71.
45. Leitch AG, Clancy U, Costello JF, Flenley DC. Effect of intravenous infusion of salbutamol on ventilatory response to carbon dioxide and hypoxia and on heart rate and plasma potassium in normal men. Br Med J 1976, 1: 365-7.